NGM Biopharmaceuticals Long-Term Debt 2011-2026 | NGM

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Quarterly Long-Term Debt NGM Biopharmaceuticals

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	1.38 M	-	4.07 M	5.38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
5.38 M	1.38 M	3.61 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	38 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Coherus BioSciences CHRS	1.46 M	$ 1.57	-3.68 %	$ 184 M	USA
Amphastar Pharmaceuticals AMPH	620 M	$ 16.87	-2.49 %	$ 789 M	USA
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
AstraZeneca PLC AZN	1.42 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Arcturus Therapeutics Holdings ARCT	20.8 M	$ 7.47	-4.6 %	$ 205 M	Israel
Athira Pharma ATHA	338 K	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	124 M	-	0.74 %	$ 768 M	Israel
Eton Pharmaceuticals ETON	21.8 M	$ 30.26	1.0 %	$ 814 M	USA
Galera Therapeutics GRTX	1.12 M	-	-32.59 %	$ 7.61 M	USA
Exelixis EXEL	173 M	$ 50.13	-1.9 %	$ 13.6 B	USA
Fortress Biotech FBIO	52.4 M	$ 2.41	4.78 %	$ 67.2 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Forte Biosciences FBRX	26.2 M	$ 23.11	-3.55 %	$ 299 M	USA
AbCellera Biologics ABCL	137 M	$ 4.09	-7.05 %	$ 1.22 B	Canada
Autolus Therapeutics plc AUTL	66.8 M	$ 1.63	2.52 %	$ 434 M	Britain
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
BioNTech SE BNTX	185 M	$ 89.55	-2.65 %	$ 21.6 B	Germany
Galectin Therapeutics GALT	20 K	$ 2.17	-7.66 %	$ 139 M	USA
Celyad Oncology SA CYAD	118 K	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	22.7 M	-	-7.31 %	$ 87 M	USA
Generation Bio Co. GBIO	80.6 M	-	-	$ 344 M	USA
IMV IMV	1.12 M	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel
Gilead Sciences GILD	22.1 B	$ 129.58	-1.88 %	$ 161 B	USA
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	15 K	$ 3.36	-3.72 %	$ 5.53 M	Israel
Aeterna Zentaris AEZS	1.93 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	2.29 M	-	1.93 %	$ 17.4 M	USA
Esperion Therapeutics ESPR	653 K	$ 3.12	-	$ 649 M	USA
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	22.1 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	9.62 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.13 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA